Maxcyte (MXCT) Retained Earnings (2020 - 2026)

Maxcyte (MXCT) has 7 years of Retained Earnings data on file, last reported at -$266.2 million in Q1 2026.

• Retained Earnings for Q1 2026 came in at -$266.2 million, down 17.22% year-over-year; the trailing twelve-month figure through Mar 2026 was -$266.2 million (down 17.22% YoY), and the FY2025 annual result was -$261.5 million, down 20.58% from the prior year.
• Retained Earnings eased to -$266.2 million in Q1 2026 per MXCT's latest filing, from -$261.5 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$118.4 million in Q1 2022 and troughed at -$266.2 million in Q1 2026.
• A 5-year average of -$189.4 million and a median of -$185.3 million in 2024 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2023 and 2026: Retained Earnings declined 28.15% in 2023, then fell 17.22% in 2026.
• A 5-year view of Retained Earnings shows it stood at -$137.9 million in 2022, then declined by 27.51% to -$175.8 million in 2023, then retreated by 23.35% to -$216.9 million in 2024, then slipped by 20.58% to -$261.5 million in 2025, then declined by 1.82% to -$266.2 million in 2026.
• Business Quant data shows MXCT's Retained Earnings at -$266.2 million in Q1 2026, -$261.5 million in Q4 2025, and -$251.9 million in Q3 2025.